English
SpanishTrusted Resources: Evidence & Education
Scientific literature and patient education texts
Orbital Decompression for Thyroid Eye Disease: Methods, Outcomes, and Complications
source: Eye
year: 2018
authors: Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM
summary/abstract:Purpose:
To determine the safety and effectiveness of orbital decompression for thyroid eye disease (TED) in our unit. To put this in the context of previously published literature.
Patients and Methods:
A retrospective case review of all patients undergoing orbital decompression for TED under the care of one orbital surgeon (SMS) between January 2009 and December 2015. A systematic literature review of orbital decompression for TED.
Results:
Within the reviewed period, 93 orbits of 55 patients underwent decompression surgery for TED. There were 61 lateral (single) wall decompressions, 17 medial one-and-a-half wall, 11 two-and-a-half wall, 2 balanced two wall, and 2 orbital fat only decompressions. For the lateral (single) wall decompressions, mean reduction in exophthalmometry (95% confidence interval (CI) was 4.2 mm (3.7-4.8), for the medial one-and-a-half walls it was 2.9 mm (2.1-3.7), and for the two-and-a-half walls it was 7.6 mm (5.8-9.4). The most common complications were temporary postoperative numbness (29% of lateral decompressions, 17% of other bony decompressions, OR 0.50, 95% CI 0.12-2.11) and new postoperative diplopia (9% of lateral decompressions, 39% of other bony decompressions, OR 6.8, 95% CI 1. 5-30.9). Systematic literature searching showed reduction in exophthalmometry for lateral wall surgery of 3.6-4.8 mm, with new diplopia 0-38% and postoperative numbness 12-50%. For other bony decompressions, reduction in exophthalmometry was 2.5-8.0 mm with new diplopia 0-45% and postoperative numbness up to 52%.
Conclusion:
Differing approaches to orbital decompression exist. If the correct type of surgery is chosen, then safe, adequate surgical outcomes can be achieved.
DOI: 10.1038/eye.2017.260
read more full text
myBinderRelated Content
-
Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid eye D...Thyroid eye disease is a disabling autoi...
-
Why is Graves’ Disease Changing the Shape of My Face?https://www.youtube.com/watch?v=cN3Djt42...
-
Risk Factors for Graves’ Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.Context: Previous association studies s...
-
Jonathan J. Dutton, MD, PhD, FACSJonathan Dutton is a Professor Emeritus ...
-
Angels Announcer Victor Rojas Stays Strong for His Wife in Her Health BattleShe braces herself for the worst. Stayin...
-
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to Focus on Thyroid Eye DiseaseFor Graves’ Disease Awareness Month in...
-
Contour Variability in Thyroid Eye Disease With Compressive Optic Neuropathy Treated With Radiation TherapyPurpose: Few studies have evaluated t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
